PSYG.F Stock Overview
A life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Psyence Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.061 |
| 52 Week Low | CA$0.008 |
| Beta | 2.04 |
| 11 Month Change | -32.95% |
| 3 Month Change | -47.32% |
| 1 Year Change | -78.01% |
| 33 Year Change | -89.53% |
| 5 Year Change | n/a |
| Change since IPO | -92.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| PSYG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 4.3% | 1.6% |
| 1Y | -78.0% | 18.8% | 32.3% |
Return vs Industry: PSYG.F underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: PSYG.F underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| PSYG.F volatility | |
|---|---|
| PSYG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PSYG.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PSYG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | n/a | psyence.com |
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions.
Psyence Group Inc. Fundamentals Summary
| PSYG.F fundamental statistics | |
|---|---|
| Market cap | US$1.50m |
| Earnings (TTM) | -US$46.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PSYG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSYG.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$65.89m |
| Earnings | -CA$65.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -113.1% |
How did PSYG.F perform over the long term?
See historical performance and comparison